Holen Sie sich die Stockscreener-App
0.7626
5.07%
0.0368
Handel nachbörslich:
.77
0.0074
+0.97%
Schlusskurs vom Vortag:
$0.7258
Offen:
$0.73
24-Stunden-Volumen:
1.62M
Relative Volume:
1.87
Marktkapitalisierung:
$223.34M
Einnahmen:
$6.23M
Nettoeinkommen (Verlust:
$-95.90M
KGV:
5.084
EPS:
0.15
Netto-Cashflow:
$-68.47M
1W Leistung:
+12.93%
1M Leistung:
-8.86%
6M Leistung:
-50.16%
1J Leistung:
-30.67%
1-Tages-Spanne:
$0.71
$0.7721
1-Wochen-Bereich:
$0.6513
$0.7773
52-Wochen-Spanne:
$0.6513
$1.93
Precigen Inc Stock (PGEN) Company Profile
Firmenname
Precigen Inc
Sektor
Branche
Telefon
301-556-9900
Adresse
20374 SENECA MEADOWS PARKWAY, GERMANTOWN, MD
Vergleichen Sie PGEN mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PGEN
Precigen Inc
|
0.7626 | 223.34M | 6.23M | -95.90M | -68.47M | -0.39 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Precigen Inc Stock (PGEN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-03-22 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2023-05-23 | Eingeleitet | JP Morgan | Neutral |
| 2022-11-18 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2021-02-25 | Eingeleitet | Stifel | Buy |
| 2021-02-22 | Eingeleitet | Wells Fargo | Overweight |
| 2021-02-18 | Eingeleitet | B. Riley Securities | Buy |
| 2020-05-08 | Eingeleitet | H.C. Wainwright | Buy |
Alle ansehen
Precigen Inc Aktie (PGEN) Neueste Nachrichten
Fmr LLC Has $327,000 Stake in Precigen, Inc. (NASDAQ:PGEN) - Defense World
Analysts Update Their Estimates For Precigen Inc - Stocks Register
Metastatic Triple Negative Breast Cancer Market Expected to Experience Major Growth by 2034, According to DelveInsight | AstraZeneca, BioEclipse Therapeutics, Precigen, Inc, Clovis Oncology, Inc - Barchart
Further weakness as Precigen (NASDAQ:PGEN) drops 16% this week, taking five-year losses to 89% - Simply Wall St
Precigen's SWOT analysis: biotech firm's stock rides on PRGN-2012 hopes - Investing.com
PGEN Stock Touches 52-Week Low at $0.71 Amid Market Challenges - Investing.com Canada
Precigen to Participate in the 2024 Cantor Global Healthcare Conference - The Eastern Progress Online
Precigen to Participate in the Stifel 2024 Healthcare Conference - The Eastern Progress Online
PGEN Stock Plummets to 52-Week Low at $0.77 Amid Market Challenges - Investing.com Nigeria
PGEN Stock Plummets to 52-Week Low at $0.77 Amid Market Challenges By Investing.com - Investing.com South Africa
Precigen (STU:I5X) Shares Outstanding (EOP) : 292.87 Mil (As of Sep. 2024) - GuruFocus.com
Precigen, Inc. (NASDAQ:PGEN) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
Bioinformatics Market to Grow by USD 13.2 Billion (2024-2028), Lower Genetic Sequencing Costs Drive Revenue, Report Highlights AI's Role in TransformationTechnavio - The Malaysian Reserve
Precigen's SWOT analysis: biotech stock focuses on RRP treatment - Investing.com
Precigen's SWOT analysis: biotech stock focuses on RRP treatment By Investing.com - Investing.com Australia
Precigen Reports Q3 2024 Financial Results - MSN
Insiders Sold Precigen Prematurely At US$1.41 With Stock Trading Higher - Simply Wall St
Precigen (NASDAQ:PGEN shareholders incur further losses as stock declines 13% this week, taking five-year losses to 86% - Yahoo Finance
Precigen, Inc. (PGEN) Reports Q3 Loss, Lags Revenue Estimates - MSN
Precigen (NASDAQ:PGEN) Given Buy Rating at HC Wainwright - Defense World
HC Wainwright Issues Negative Outlook for Precigen Earnings - MarketBeat
PGEN stock touches 52-week low at $0.78 amid market challenges - Investing.com Canada
HC Wainwright Reiterates Buy Rating for Precigen (NASDAQ:PGEN) - MarketBeat
Precigen Inc. (PGEN) Quarterly 10-Q Report - Quartz
Precigen Inc (PGEN) Q3 2024 Earnings: EPS Misses at $(0.09), Rev - GuruFocus.com
Precigen, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Precigen earnings missed, revenue fell short of estimates By Investing.com - Investing.com UK
Precigen Reports Third Quarter 2024 Financial Results and Business Updates - Nasdaq
Precigen (NASDAQ:PGEN) Shares Cross Below Two Hundred Day Moving AverageTime to Sell? - MarketBeat
Precigen CEO to Present at Stifel 2024 Healthcare Conference: Gene Therapy Innovation Spotlight | PGEN Stock News - StockTitan
Precigen, Inc. (NASDAQ:PGEN) Receives $7.00 Consensus Price Target from Brokerages - Defense World
Precigen, Inc. (NASDAQ:PGEN) Receives $7.00 Consensus Target Price from Analysts - MarketBeat
PGEN (Precigen) EBITDA per Share : $-0.52 (TTM As of Jun. 2024) - GuruFocus.com
Precigen Announces Pricing of $30.0 Million Public Offering of C - GuruFocus.com
Iridian Asset Management LLC CT Grows Stock Position in Precigen, Inc. (NASDAQ:PGEN) - MarketBeat
PGEN stock touches 52-week low at $0.82 amid market challenges - Investing.com Australia
Precigen to Announce Fourth Quarter and Full Year 2023 Financial Results on March 19th - GuruFocus.com
High Growth Tech Stocks To Watch In October 2024 - Simply Wall St
Should you Hold Precigen (PGEN)? - Insider Monkey
Precigen, Inc. (NASDAQ:PGEN) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
A company insider recently bought 58,823 shares of Precigen Inc [PGEN]. Should You Buy? - Knox Daily
Precigen reclaims rights after terminating license agreement By Investing.com - Investing.com Australia
Precigen Inc (PGEN) stock analysis: A simple moving average approach - US Post News
Precigen reclaims rights after terminating license agreement - Investing.com India
Alaunos Therapeutics Ends Licensing Deal, Reassesses Strategy - Yahoo Finance
Precigen Terminates License Agreement With Alaunos Therapeutics - MarketWatch
Finanzdaten der Precigen Inc-Aktie (PGEN)
Umsatz
Nettogewinn
Free Cashflow
ENV
Precigen Inc-Aktie (PGEN) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| KIRK RANDAL J | Director |
Aug 09 '24 |
Buy |
0.85 |
23,529,411 |
19,999,999 |
64,547,214 |
| KIRK RANDAL J | Director |
Mar 09 '24 |
Option Exercise |
0.00 |
213,675 |
0 |
32,051,461 |
| KIRK RANDAL J | Director |
Dec 28 '23 |
Buy |
1.41 |
96,686 |
136,327 |
1,096,686 |
| KINDLER JEFFREY B | Director |
Dec 28 '23 |
Sale |
1.41 |
96,686 |
136,327 |
238,275 |
2.88%
2.65%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):